A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
Abstract
:1. Background
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Etienne, G.; Guilhot, J.; Rea, D.; Rigal-Huguet, F.; Nicolini, F.; Charbonnier, A.; Guerci-Bresler, A.; Legros, L.; Varet, B.; Gardembas, M.; et al. Long-Term Follow-up of the French Stop Imatinib (STIM1) Study in Patients with Chronic Myeloid Leukemia. J. Clin. Oncol. 2017, 35, 298–305. [Google Scholar] [CrossRef] [Green Version]
- Campiotti, L.; Suter, M.B.; Guasti, L.; Piazza, R.; Gambacorti-Passerini, C.; Grandi, A.M.; Squizzato, A. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. Eur. J. Cancer 2017, 77, 48–56. [Google Scholar] [CrossRef]
- Fava, C.; Rege-Cambrin, G.; Dogliotti, I.; Cerrano, M.; Berchialla, P.; Dragani, M.; Rosti, G.; Castagnetti, F.; Gugliotta, G.; Martino, B.; et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica 2019, 104, 1589–1596. [Google Scholar] [CrossRef]
- Saussele, S.; Richter, J.; Guilhot, J.; Gruber, F.X.; Hjorth-Hansen, H.; Almeida, A.; Mjanssen, J.J.W.; Mayer, J.; Koskenvesa, P.; Panayiotidis, P.; et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018, 19, 747–757. [Google Scholar] [CrossRef] [Green Version]
- Rea, D.; Nicolini, F.E.; Tulliez, M.; Guilhot, F.; Guilhot, J.; Guerci-Bresler, A.; Gardembas, M.; Coiteux, V.; Guillerm, G.; Legros, L.; et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: Interim analysis of the STOP 2G-TKI study. Blood 2017, 129, 846–854. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ross, D.M.; Masszi, T.; Casares, M.T.G.; Hellmann, A.; Stentoft, J.; Conneally, E.; Garcia-Gutierrez, V.; Gattermann, N.; le Coutre, P.D.; Martino, B.; et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J. Cancer Res. Clin. Oncol. 2018, 144, 945–954. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Imagawa, J.; Tanaka, H.; Okada, M.; Nakamae, H.; Hino, M.; Murai, K.; Ishida, Y.; Kumagai, T.; Sato, S.; Ohashi, K.; et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): A multicentre phase 2 trial. Lancet Haematol. 2015, 2, e528–e535. [Google Scholar] [CrossRef]
- Hochhaus, A.; Baccarani, M.; Silver, R.T.; Schiffer, C.; Apperley, J.F.; Cervantes, F.; Clark, R.E.; Cortes, J.E.; Deininger, M.W.; Guilhot, F.; et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020, 34, 966–984. [Google Scholar] [CrossRef] [Green Version]
- Dulucq, S.; Astrugue, C.; Etienne, G.; Mahon, F.X.; Benard, A. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: A systematic review of literature with a meta-analysis of studies over the last ten years. Br. J. Haematol. 2020, 189, 452–468. [Google Scholar] [CrossRef]
- Ross, D.M.; Branford, S.; Seymour, J.F.; Schwarer, A.P.; Arthur, C.; Yeung, D.T.; Dang, P.; Goyne, J.M.; Slader, C.; Filshie, R.J.; et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 2013, 122, 515–522. [Google Scholar] [CrossRef]
- Mahon, F.X.; Réa, D.; Guilhot, J.; Guilhot, F.; Huguet, F.; Nicolini, F.; Legros, L.; Charbonnier, A.; Guerci, A.; Varet, B.; et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11, 1029–1035. [Google Scholar] [CrossRef]
- Kong, J.H.; Winton, E.F.; Heffner, L.T.; Chen, Z.; Langston, A.A.; Hill, B.; Arellano, M.; El-Rassi, F.; Kim, A.; Jillella, A.; et al. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia? Cancer 2017, 123, 2482–2488. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Branford, S.; Yeung, D.T.; Prime, J.A.; Choi, S.Y.; Bang, J.H.; Park, J.E.; Kim, D.-W.; Ross, D.M.; Hughes, T.P. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: Implications for monitoring and management. Blood 2012, 119, 4264–4271. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jabbour, E.J.; Siegartel, L.R.; Lin, J.; Lingohr-Smith, M.; Menges, B.; Makenbaeva, D. Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model. J. Med. Econ. 2018, 21, 1036–1040. [Google Scholar] [CrossRef] [PubMed]
- Shanmuganathan, N.; Braley, J.A.; Yong, A.S.; Hiwase, D.K.; Yeung, D.T.; Ross, D.M.; Hughes, T.P.; Branford, S. Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood 2019, 134, 85–89. [Google Scholar] [CrossRef] [PubMed]
- Cross, N.C.P.; White, H.E.; Colomer, D.; Ehrencrona, H.; Foroni, L.; Gottardi, E.; Lange, T.; Lion, T.; Polakova, K.M.; Dulucq, S.; et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015, 29, 999–1003. [Google Scholar] [CrossRef] [Green Version]
- Recently Updated NCCN Clinical Practice Guidelines in OncologyTM. Available online: https://www.nccn.org/professionals/physician_gls/recently_updated.aspx (accessed on 16 August 2020).
- Chronic Myeloid Leukaemia: ESMO Clinical Practice Guidelines for diagnosis, Treatment and Follow-up—Annals of Oncology. Available online: https://www.annalsofoncology.org/article/S0923-7534(19)42147-9/fulltext (accessed on 16 August 2020).
- Bernardi, S.; Malagola, M.; Zanaglio, C.; Polverelli, N.; Dereli Eke, E.; D’Adda, M.; Farina, M.; Bucelli, C.; Scaffidi, L.; Toffoletti, E.; et al. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med. 2019, 8, 2041–2055. [Google Scholar] [CrossRef]
- Lee, S.E.; Choi, S.Y.; Song, H.Y.; Kim, S.H.; Choi, M.Y.; Park, J.S.; Kim, H.-J.; Kim, S.-H.; Zang, D.Y.; Oh, S.; et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: The KID study. Haematologica 2016, 101, 717–723. [Google Scholar] [CrossRef] [Green Version]
- Mori, S.; Vagge, E.; Le Coutre, P.; Abruzzese, E.; Martino, B.; Pungolino, E.; Elena, C.; Pierri, I.; Assouline, S.; D’Emilio, A.; et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. Am. J. Hematol. 2015, 90, 910–914. [Google Scholar] [CrossRef]
- Rea, D.; Cayuela, J.M.; Dulucq, S.; Etienne, G. Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED). Blood 2017, 130, 318. [Google Scholar] [CrossRef]
- Clark, R.E.; Polydoros, F.; Apperley, J.F.; Milojkovic, D.; Rothwell, K.; Pocock, C.; Byrne, J.; Lavallade, H.; Osborne, W.; Robinson, L.; et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): A non-randomised, phase 2 trial. Lancet Haematol. 2019, 6, e375–e383. [Google Scholar] [CrossRef] [Green Version]
- Rousselot, P.; Loiseau, C.; Delord, M.; Besson, C.; Cayuela, J.M.; Spentchian, M. A Report on 114 Patients Who Experienced Treatment Free Remission in a Single Institution during a 15 Years Period: Long Term Follow-up, Late Molecular Relapses and Second Attempts. Blood 2019, 134, 27. [Google Scholar] [CrossRef]
- Rea, D.; Nicolini, F.E.; Tulliez, M.; Rousselot, P.; Gardembas, M.; Etienne, G.; Guilhot, F.; Guilhot, J.; Guerci, A.; Escoffre-Barbe, M.; et al. Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update. Blood 2019, 134, 30. [Google Scholar] [CrossRef]
- Lee, S.E.; Park, J.S.; Kim, H.J.; Kim, S.H.; Zang, D.Y.; Oh, S.; Do, Y.R.; Choi, Y.; Kwak, J.-Y.; Kim, J.-A.; et al. Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS). Blood 2019, 134, 1643. [Google Scholar] [CrossRef]
- Claudiani, S.; Metelli, S.; Kamvar, R.; Szydlo, R.; Khan, A.; Byrne, J.; Gallipoli, P.; Bulley, S.J.; Horne, G.A.; Rothwell, K.; et al. Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). Blood 2019, 134, 26. [Google Scholar] [CrossRef]
Months after Discontinuation | Patients with MMR Loss (%) |
---|---|
1 | 3 (3.5) |
2 | 7 (8.1) |
3 | 14 (16.3) |
4 | 23 (26.7) |
5 | 12 (14.0) |
6 | 6 (7.0) |
7 | 7 (8.1) |
8 | 3 (3.5) |
9 | 1 (1.2) |
11 | 1 (1.2) |
12 | 1 (1.2) |
13+ | 8 (9.3) |
MR3 | MR4 | MR4.5 | MR5 | p | |
---|---|---|---|---|---|
N° of patients | 7 | 80 | 63 | 24 | 0.849 1 |
Months between discontinuation and MMR loss (median (IQR)) | 3.14 [1.93, 6.83] | 4.26 [2.94, 5.26] | 3.44 [3.09, 3.85] | 3.21 [3.17, 3.21] |
Study | Timing of Monitoring | Study | Timing of Monitoring |
---|---|---|---|
STIM A-STIM | Once monthly for 12 months Once every 2 months for 12 months Once every 3 months thereafter | STOP2GTKI | Once monthly for 12 months Once every 2–3 months for 12 months Once every 36 months for up to 6 years |
EURO-SKI | Once monthly for 6 months Once every 6 weeks for 6 months Once every 3 months thereafter | KID | Every month for 6 months Once every 2 months for 12 months Once every three months thereafter |
DADI | Once monthly for 12 months Once every 3 months for 12 months Once every 6 months thereafter | LAST | Once monthly for 6 months Once every 2 months in months 7–24 Once every three months thereafter |
JALGS- STIM213 | Once monthly for 6 months Once every 2 months for 6 months Once every 3 months thereafter | ESMO | Once monthly for 6 months Every 6 weeks for 6 months Once every 3 months thereafter |
ENEST freedom | Once monthly for 12 months Once every 6 weeks for 12 months Once every 3 months thereafter | NCCN | Once monthly for 12 months Every 6 weeks for 12 months Once every 3 months thereafter |
TWISTER | Once monthly for 12 months Once every 2 months for 12 months Once every 3 months thereafter | ELN 2020 | Once monthly for 6 months Once every 2 months for months 6–12 Once every three months thereafter |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dragani, M.; Rege Cambrin, G.; Berchialla, P.; Dogliotti, I.; Rosti, G.; Castagnetti, F.; Capodanno, I.; Martino, B.; Cerrano, M.; Ferrero, D.; et al. A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. J. Clin. Med. 2020, 9, 3692. https://doi.org/10.3390/jcm9113692
Dragani M, Rege Cambrin G, Berchialla P, Dogliotti I, Rosti G, Castagnetti F, Capodanno I, Martino B, Cerrano M, Ferrero D, et al. A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. Journal of Clinical Medicine. 2020; 9(11):3692. https://doi.org/10.3390/jcm9113692
Chicago/Turabian StyleDragani, Matteo, Giovanna Rege Cambrin, Paola Berchialla, Irene Dogliotti, Gianantonio Rosti, Fausto Castagnetti, Isabella Capodanno, Bruno Martino, Marco Cerrano, Dario Ferrero, and et al. 2020. "A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation" Journal of Clinical Medicine 9, no. 11: 3692. https://doi.org/10.3390/jcm9113692